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Extracellular matrix (ECM) mechanical cues have powerful effects on cell proliferation, 18 
differentiation and death. Here, starting from an unbiased metabolomics approach, we identified 19 
synthesis of neutral lipids as a general response to mechanical signals delivered by cell-matrix 20 
adhesions. Extracellular physical cues reverberate on the mechanical properties of the Golgi 21 
apparatus and regulate the Lipin-1 phosphatidate phosphatase. Conditions of reduced 22 
actomyosin contractility lead to inhibition of Lipin-1, accumulation of SCAP/SREBP to the Golgi 23 
apparatus and activation of SREBP transcription factors, in turn driving lipid synthesis and 24 
accumulation. This occurs independently of YAP/TAZ, mTOR and AMPK, and in parallel to the 25 
feedback control by sterols. Regulation of SREBP can be observed in a stiffened diseased tissue, 26 
and contributes to the pro-survival activity of ROCK inhibitors in pluripotent stem cells. We 27 
thus identify a general mechanism centered on Lipin-1 and SREBP that links the physical cell 28 
microenvironment to a key metabolic pathway. 29 
 30 
Introduction 31 
Each tissue has a specific composition of its extracellular matrix (ECM), which is associated to 32 
distinctive physical and mechanical properties. These mechanical properties are important for tissue 33 
structure, but also control cell function in physiology and disease1,2. Cells sense the mechanical 34 
properties of the ECM through integrin receptors, and measure them by adjusting the contractility of 35 
their F-actin cytoskeleton: contractility is maximal when cells are free to spread on stiff ECM substrata, 36 
while it is progressively decreased on a soft ECM or in conditions of limited spreading. This is 37 
sufficient to control the switch between proliferation, differentiation and death in very diverse cell 38 
types, by regulating intracellular signaling pathways such as YAP/TAZ3,4 and SRF5,6. In support of this 39 
model, inhibition of key players that maintain F-actin contractility including the small GTPase RHO, 40 
ROCK (RHO kinase), MLCK (myosin light chain kinase) and non-muscle myosin (NMII) induce 41 
similar responses to a soft ECM1. Yet, what other general aspects of cell biology are regulated by 42 
mechanical cues, and through which mechanism(s), remain largely unexplored. This is especially true 43 
in the case of metabolism, a fundamental engine that is constantly remodeled to match the energetic 44 
and biosynthetic requirements of the cell, whose connections to mechanical cues are only starting to 45 
emerge7,8. 46 
 47 
Actomyosin regulates lipid metabolism 48 
To test in an unbiased manner the possibility that actomyosin contractility regulates metabolism we 49 
compared by global metabolomics cells in conditions of high contractility (i.e. plated on plastics) with 50 
cells in conditions of low contractility, by inhibiting ROCK and MLCK. Analysis of steady-state levels 51 
of multiple metabolites indicated clear differences between controls and treated cells (Fig. 1a and 52 
Supplementary Fig. 1a-e); the most significant and quantitative changes, which were maintained or 53 
increased between 6 and 24 hours, were the accumulation of several lipid molecules (Supplementary 54 
Fig. 1e and Ref.9). 55 
We validated this initial observation with a targeted lipidomic analysis at 24 hours, which 56 
confirmed accumulation of triglycerides, diacylglycerols, lyso-phospholipids and ceramides, while 57 
many other lipid species remained overall unchanged (Fig. 1b-d, Supplementary Fig. 1f-h and Ref.9). 58 
This was accompanied by increased free and total fatty acids and cholesterol in cell extracts (Fig. 1e,f), 59 
and by a corresponding accumulation of cholesterol and neutral lipids in fixed cells (by Filipin and Oil-60 
Red-O stains, respectively – Fig. 1g, Supplementary Fig. 1i-k). Such accumulation was visible after 6 61 
hours of treatment, and sustained up to 48 hours (Supplementary Fig. 1l). A similar effect was observed 62 
by replacing Y27632 with Fasudil, an alternative ROCK inhibitor, or by using Y27632 or ML7 63 
inhibitors alone (Fig. 1g). Accumulation of lipids was mainly due to increased synthesis, because it was 64 
impaired in cells where rate-limiting enzymes of cholesterol and fatty-acid synthesis were inhibited by 65 
Cerivastatin or TOFA (Fig. 1g). Finally, lipid accumulation was a general response to ECM mechanical 66 
cues and actomyosin contractility because expression of the RHO inhibitor C3, treatment of cells with 67 
the NMII small-molecule inhibitor Blebbistatin, or seeding cells on a soft vs. stiff fibronectin-coated 68 
polyacrylamide hydrogels induced a coherent accumulation of cholesterol and lipid droplets (Fig. 1h-i). 69 
We then extended these findings in multiple cell types including primary, immortalized, and 70 
transformed cells, of both epithelial and connective tissue origin, indicating that lipid accumulation is a 71 
widespread response to conditions of reduced actomyosin contractility (Fig. 1j,k and Supplementary 72 
Fig. 1m,n). 73 
 74 
ECM mechanical cues regulate a genetic program for lipid synthesis 75 
Thinking of potential mechanisms underlying this metabolic shift, we tested an involvement of the 76 
Hippo pathway. YAP/TAZ are inhibited by reduced actomyosin contractility3,4, but their knockdown 77 
did not cause lipid accumulation comparable to ROCK/MLCK inhibition (Supplementary Fig. 2a). 78 
Similarly, stable TAZ-S4A active mutant expression was not sufficient to prevent lipid accumulation 79 
upon ROCK/MLCK inhibition (Supplementary Fig. 2b). LATS1/2 Hippo kinases can be activated by 80 
reduced actomyosin contractility10, but genetics indicated that LATS2 inhibits lipid metabolism11, 81 
which was incompatible with our results. This suggested the regulation of an alternative pathway that 82 
we sought to identify by performing microarray analysis of MCF10ATk1 cells treated with 83 
Y27632+ML7, followed by gene list enrichment analysis. As shown in Fig. 2a,b we found a striking 84 
enrichment of signatures related to cholesterol and fatty acid synthesis among the upregulated genes, 85 
including many known SREBP1 and SREBP2 (sterol regulatory element binding proteins) targets, 86 
pointing to activation of these transcription factors12,13. We thus validated activation of SREBP1/2 by a 87 
luciferase reporter for SREBP transcriptional activity, by qPCR, and in multiple cell lines (Fig. 2c,d 88 
and Supplementary Fig. 2d-f). Importantly, we also observed a coherent induction of SREBP target 89 
genes in cells cultured on soft hydrogels (Fig. 2e-g), while YAP/TAZ inhibition had no effects on 90 
SREBP activity (Supplementary Fig. 2g,h). Of note, among the validated SREBP targets LDLR (low 91 
density lipoprotein receptor) expression correlated with increased fatty acid uptake (Supplementary 92 
Fig. 2i), and ACSS2 (acyl-CoA synthetase short chain family member 2) with increased usage of acetate 93 
for lipid synthesis14 (Supplementary Fig. 2j). 94 
 95 
ECM mechanical cues control lipid synthesis through direct regulation of SREBP1/2 activity 96 
SREBP are produced as transmembrane proteins resident in the ER (endoplasmic reticulum) (see 97 
model in Supplementary Fig. 3a): in the presence of sterols and fatty acids, SCAP (SREBP cleavage-98 
activating protein) and Insig (insulin-induced gene) proteins bind SREBP and limit their transport to 99 
the Golgi apparatus; in absence of lipids, conformational changes in SCAP and Insig enable the 100 
quantitative transport of SCAP and SREBP to the Golgi, where SREBP are processed by the S1P (site-101 
1 protease) and S2P (site-2 protease) Golgi-resident enzymes. This in turn releases the cytoplasmic 102 
portion of SREBP that is free to accumulate into the nucleus to regulate gene transcription12,13. 103 
Prompted by the observation that mechanical cues regulate SREBP activity, we sought to 104 
causally link SREBP activity with the effects of mechanical cues. As shown in Fig. 3a-c and 105 
Supplementary Fig. 3b,c knockdown of SREBP1/2 inhibited expression of lipid enzymes and lipid 106 
accumulation in response to Y27632+ML7 and to a soft hydrogel. We then probed endogenous 107 
SREBP2 localization and observed an early concentration to the Golgi apparatus (2 hours), closely 108 
followed by nuclear accumulation (4-6 hours), upon treatment with ROCK/MLCK inhibitors (Fig. 3d 109 
and Supplementary Fig. 3d-g). Nuclear accumulation of SREBP2 started to fade at 24 hours and 110 
became almost undetectable at 48 hours of treatment (Fig. 3d), likely due to accumulation of lipids 111 
eventually restraining SREBP activation. Moreover, nuclear accumulation was reversible, since 112 
washout of the inhibitors led to the rapid disappearance of nuclear SREBP2 (Fig. 3d). In keeping with a 113 
general effect of mechanical cues, nuclear SREBP2 was observed upon transfection of the C3 RHO 114 
inhibitor, treatment with Blebbistatin, and on soft hydrogels (Fig. 3d and Supplementary Fig. 3f,g). 115 
This was associated with accumulation of cleaved SREBP1 and SREBP2 in nuclear extracts (Fig. 3e 116 
and Supplementary Fig. 3h). In line with a direct effect, nuclear accumulation of SREBP2 occurred in 117 
absence of protein synthesis (Fig. 3f,g and Supplementary Fig. 3i,j). Finally, ROCK/MLCK inhibitors 118 
could not stimulate further LDLR-luciferase in cells engineered to express only a mature form of 119 
SREBP2 (Fig. 3h), indicating regulation of SREBP2 at the level of cleavage and not of nuclear 120 
stability. 121 
 122 
Inhibition of SREBP activity by pathological tissue stiffness 123 
To find evidence that this regulation also occurs in vivo, we queried gene expression data obtained by 124 
comparing patient-matched normal skin with keloid scars15, a fibroproliferative disorder characterized 125 
by increased tissue stiffness and whose expansion is linked to mechanical stress16,17. Strikingly, several 126 
SREBP target genes were consistently and uniformly downregulated in stiffened keloids across all 127 
patients, supporting our model (Fig. 3i). Of note, this finding nicely parallels the so-far unexplained 128 
decrease in lipids and cholesterol-esters observed in keloids18. As a control, we also found upregulation 129 
of several YAP/TAZ target genes (Fig. 3i), in line with stiffness-induced YAP/TAZ activity during 130 
fibrosis19,20. Thus, cytoskeletal tension is a relevant input to regulate SREBP in vitro and in at least one 131 
human pathological tissue. 132 
 133 
ECM mechanical cues regulate SCAP localization and function 134 
We next probed the subcellular localization of core SREBP regulators. While Insig1 and S1P remained 135 
correctly confined to the ER and the Golgi apparatus, respectively (Supplementary Fig. 4a,b), we 136 
observed translocation of SCAP to the Golgi apparatus by plating cells on soft hydrogels and after 137 
inhibition of RHO or ROCK/MLCK (Fig. 4a,b and Supplementary Fig. 4c). This was instrumental for 138 
the regulation of SREBP by mechanical cues, because both SCAP knockdown and treatment of cells 139 
with 25-hydroxycholesterol, a dominant inhibitor of SCAP transport21, decreased SREBP activation 140 
(Fig. 4c,e and Supplementary Fig. 4d). In line, treating cells with the S1P inhibitor PF429242 also 141 
prevented activation of SREBP (Fig. 4d,e). This indicates that actomyosin contractility prevents 142 
accumulation of SCAP/SREBP to the Golgi apparatus and the exposure of SREBP to Golgi proteases. 143 
 144 
Lipid synthesis contributes to the beneficial effects of ROCK inhibitors in hPSC 145 
To expand the functional implications of these findings we used human Pluripotent Stem Cells (hPSC). 146 
These cells require treatment with the Y27632 ROCK inhibitor to survive single-cell dissociation, 147 
while they thrive without inhibitor once they have attached to the substrate22,23. We thus tested the idea 148 
that Y27632 might promote survival of hPSC by enhancing lipid synthesis. We first confirmed that 149 
Y27632 induces lipid accumulation also in these cells (Supplementary Fig. 4e). We then challenged 150 
Y27632-induced survival of hPSC seeded as single cells by using very low doses of lipid synthesis 151 
inhibitors (Cerivastatin and TOFA), and found that hPSC did not survive (Fig. 4f, single cells); the 152 
same dose of inhibitors was instead inconsequential for cell survival of already-established hPSC 153 
colonies, when Y27632 is not required (Fig. 4f, colonies). In line, both treatment of cells with 25-154 
hydroxycholesterol and transfection of SREBP1/2 siRNAs impaired Y27632-induced single-cell 155 
survival (Fig. 4g,h). These results suggest that isolated hPSC are highly dependent on lipid synthesis, 156 
and that ROCK inhibition promotes their survival, at least in part, by sustaining SREBP activity. 157 
 158 
Uncoupling actomyosin contractility from intracellular cholesterol trafficking 159 
One possibility to explain our findings is that reduced actomyosin contractility leads to reduced levels 160 
of sterols at the ER because of decreased transport of extracellular cholesterol from the 161 
endosome/lysosome to the ER by the NPC1 transporter12,13. We excluded this scenario based on the 162 
following observations: (i) cholesterol accumulation in response to Y27632+ML7 was decreased in 163 
cells with inhibited synthesis or with SREBP1/2 knockdown (see above), indicating it is a secondary 164 
effect; (ii) cholesterol accumulation occurred after SREBP activation, and with a delayed kinetics 165 
compared to inhibition of the NPC1 transporter with U18666A (Supplementary Fig. 5a); (iii) while 166 
U18666A induced accumulation of cholesterol in LAMP2-encircled lysosomal structures, as expected, 167 
only few Y27632+ML7-induced cholesterol dots were positive for LAMP2 (Supplementary Fig. 5b); 168 
(iv) treatment with Y27632+ML7, at difference with U18666A or with serum (and, thus, LDL-169 
cholesterol) deprivation, did not cause concentration of the ER cholesterol-sensing protein OSBP to the 170 
Golgi apparatus at early time-points24,25 (Supplementary Fig. 5c). 171 
 172 
Linking actomyosin contractility to the Lipin-1/ARF1 SREBP-regulatory axis 173 
Looking for alternative mechanisms, we reasoned that among the known SREBP-regulatory inputs, two 174 
act independently of sterol levels: ARF1 and Lipin-1. The ARF1 (ADP ribosylation factor 1) small G 175 
protein regulates Golgi dynamics26,27, and inhibits SREBP28-30. The precise mechanism remained 176 
incompletely understood, because Walker and colleagues showed that ARF1 prevents S1P from 177 
shuttling to the ER, while Nakayama and colleagues showed that the ARF1 effector COPI prevents 178 
accumulation of SCAP/SREBP to the Golgi. Lipin-1 is a phosphatase that converts phosphatidates into 179 
diacylglycerols at cytoplasmic membranes31, and also an inhibitor of SREBP activity29,32. Interestingly, 180 
ARF1 recruitment to the Golgi apparatus and formation of COPI-coated vesicles requires 181 
diacylglycerols33-36, such that inhibition of Lipin-1 activity can cause ARF1 dissociation from Golgi 182 
membranes and ARF1 inhibition29,35. This suggested us that reduced actomyosin contractility might 183 
induce SREBP activity by inhibiting Lipin-1/ARF1 (see model in Supplementary Fig. 5d). 184 
We first verified that inhibition of Lipin-1, ARF1 or COPI induce SREBP activation, SCAP 185 
accumulation at the Golgi apparatus and lipid accumulation in our systems (Fig. 5a-f and 186 
Supplementary Fig. 5e). We then indirectly gauged Lipin-1 activity by monitoring its association with 187 
microsomes37,38 or by monitoring Golgi membrane diacylglycerol (DG) content with the DG-binding 188 
domain of PKD1 (GFP-PKD-KD)35,39,40, and found that inhibition of ROCK/MLCK rapidly caused 189 
Lipin-1 dissociation from microsomes (Fig. 5g) and decreased GFP-PKD-KD co-localization with the 190 
Golgi apparatus (Fig. 5h). ROCK/MLCK inhibition also decreased ARF1 activity (Fig. 5i) and ARF1 191 
recruitment to the Golgi apparatus (Fig. 5j). Moreover, both Lipin-1 and ROCK/MLCK inhibition 192 
induce similar remodeling of Golgi morphology at late time-points (Supplementary Fig. 5f,g), a 193 
phenotype previously observed in cells depleted of GBF1/ARF128. We did not observe a general 194 
redistribution of a fluorescent KDEL reporter (Supplementary Fig. 5h), indicating overall intact 195 
transports between ER and Golgi. Collectively, our data indicate that mechanical cues control Lipin-1 196 
activity, causing altered ARF1-dependent trafficking of SCAP/SREBP between the Golgi and the ER. 197 
 198 
Actomyosin contractility controls SREBP through Lipin-1, but independently from 199 
AMPK/mTOR 200 
We then explored how Lipin-1 is regulated. Lipin-1 activity and association to cytoplasmic membranes 201 
can be inhibited by phosphorylation32,37,38. We checked Lipin-1 overall phosphorylation levels, but we 202 
did not observe major changes of the Lipin-1 migratory pattern (Fig. 6a). We also monitored Lipin-1 203 
subcellular localization by immunofluorescence, and found that reduced contractility partially shifted 204 
FLAG-Lipin-1 towards the nucleus (Fig. 6b,c). Nuclear Lipin-1 has been associated with inactivation 205 
of SREBP32; since we observed a partial nuclear accumulation of Lipin-1 in conditions of active 206 
SREBP, we then wondered what pool of Lipin-1 was relevant in our cells. For this we compared wild-207 
type Lipin-1 (WT) with a nuclear phospho-mutant (17S/A) and with Lipin-1 isoforms that we designed 208 
to constitutively associate with ER/Golgi membranes (MB-Lipin-1 and MB*-Lipin-1 - see Fig. 6c), and 209 
used these to challenge the effects of reduced contractility. While the WT and 17S/A mutant were 210 
inactive, expression of membrane-associated Lipin-1 counteracted SREBP activity (Fig. 6d,e) and lipid 211 
accumulation (Fig. 6f). Also the SUMOylation41 and acetylation42 Lipin-1 mutants were inactive in the 212 
same assay (Supplementary Fig. 6a). Collectively, these results indicate that reduced contractility 213 
inhibits the affinity of Lipin-1 for ER/Golgi membranes, leading to nuclear localization of Lipin-1 as 214 
secondary effect. This occurs independently from mTOR, a known Lipin-1 regulatory input 215 
(Supplementary Fig. 6b,c), and also from AMPK, a main metabolic regulator (Supplementary Fig. 216 
6d,e). 217 
 218 
The Golgi apparatus responds to extracellular and intracellular forces 219 
We finally sought to obtain some insight into how extracellular mechanical cues influence signaling at 220 
the Golgi apparatus. Transmission of forces from the ECM entail activation of signaling molecules at 221 
focal adhesions1 but also occur in a direct fashion, for example by stretching the plasma membrane, or 222 
owing to anchoring of stress fibers to the nuclear lamina43,44. Whether the Golgi apparatus might 223 
respond in a similar fashion has not been explored, but Golgi cisternae are embedded in a complex 224 
cytoskeletal network45,46, and the Golgi microenvironment is endowed of an intrinsic mechanical 225 
rigidity which depends on ROCK/MLCK47. To measure the response of Golgi rigidity to external 226 
physical cues we plated cells on small fibronectin-coated micropatterns, to which cells respond by 227 
decreasing actomyosin contractility48, and by accumulating SCAP to the Golgi apparatus (Fig. 7a).We 228 
then measured Golgi rheology by pushing on the Golgi apparatus a cytoplasmic bead immobilized in a 229 
laser optical trap (see methods and Supplementary Fig. 7a). Analysis of the averaged relaxation curves 230 
(Fig. 7b and Supplementary Fig. 7b) indicated a lower rigidity of the Golgi apparatus in micropatterned 231 
cells, apparent from reduction of the bead step amplitude, the rigidity index, and the frequency of bead 232 
ejection (Fig. 7c). As a control, moving the bead away from the Golgi showed that the overall 233 
cytoplasmic stiffness is not altered (Supplementary Fig. 7c). This experiment indicates that Golgi 234 
stiffness is coupled, directly or indirectly, to the mechanical properties of the ECM. Strikingly, with 235 
this set-up we also observed that direct application of force to the Golgi apparatus was sufficient to 236 
induce recruitment of the GFP-PKD-KD reporter (Fig. 7d,e), in line with higher Lipin-1 activity in 237 
cells developing higher contractile forces (see above). 238 
 239 
Discussion 240 
Seminal work demonstrating that cells sense ECM mechanical cues set the array of bona-fide 241 
mechanoregulated phenotypes in vitro. Yet, what other general cell phenotypes are regulated by 242 
mechanical cues remains largely unexplored. Here we focused on cell metabolism and identified 243 
neutral lipid and cholesterol synthesis as a general response to reduced actomyosin contractility and to 244 
a soft ECM microenvironment. We propose that decreased extracellular forces reverberate on Golgi 245 
rheology and inactivate Lipin-1, causing alteration of diacylglycerol at the Golgi apparatus, reduced 246 
recruitment of ARF1, and ultimately leading to activation of SREBP1/2 transcription factors. As such, 247 
our data provide a missing upstream input for the Lipin-1 and ARF1 SREBP-regulatory axis, whose 248 
players were previously identified in C. elegans29, and validates the idea that continuous shuttling of 249 
SCAP/SREBP from the Golgi to the ER is a significant mechanism limiting their activation30. These 250 
findings led us to revisit the requirement of isolated human pluripotent stem cells for ROCK inhibition, 251 
that we found linked to the ability to sustain SREBP activity and lipid synthesis. We speculate this 252 
might underlie the beneficial effect of ROCK inhibition observed for isolation of other primary stem-253 
cell populations49-51. These findings also indicate that physiological or pathological conditions leading 254 
to altered tissue stiffness may impact SREBP activity and lipid metabolism; strikingly, we could obtain 255 
a proof-of-principle for this in human keloid scars, providing a plausible explanation for reduced 256 
triglycerides and cholesteryl-esters18. Thus, we here identify an unexpected and widespread 257 
mechanoresponsive phenotype, and its main underlying mechanism. Our findings raise interesting 258 
questions on how Lipin-1 is regulated in this context; we speculate that Lipin-1 macromolecular 259 
complexes observed on supported lipid bilayers in vitro52 are endowed of curvature-sensing ability, 260 
which might link Lipin-1 activity to the rheology of Golgi membranes and the cytoskeleton. In future, 261 
it will be interesting to test whether ECM mechanical cues affect other functions of the Golgi, of Lipin-262 
1 signaling and of ARF1, and how these impact the response of normal and diseased tissues to 263 
mechanical cues. 264 
 265 
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Figure legends 427 
 428 
Figure 1. Actomyosin contractility and ECM mechanical cues regulate lipid synthesis. 429 
a, Principal component analysis of metabolites altered by global metabolomics in MCF10ATk1 human 430 
mammary epithelial cells treated for 6 or 24 hours with 20μM Y27632 ROCK inhibitor and 20μM 431 
ML7 MLCK inhibitor to inhibit actomyosin contractility (hereafter YM, n=6 biologically independent 432 
samples), as compared to vehicle (DMSO, n=4 biologically independent samples). b, Volcano plot of 433 
lipid molecules altered in MCF10ATk1 cells treated for 24 hours with YM, as measured by targeted 434 
lipidomics. n=5 biologically independent samples per condition. TG, triacylglycerols; DG, 435 
diacylglycerols; LysoPC, lyso-phosphatidylcholines; Cer, ceramides. c,d, TG (c) and DG (d) levels in 436 
MCF10ATk1 cells treated with YM for 24 hours, as measured by mass spectrometry. Only the five 437 
most abundant species are shown. e,f, Fatty acids (e, n=5 biologically independent samples per 438 
condition) and cholesterol (f, n=9 biologically independent samples per condition) in MCF10ATk1 439 
cells treated with YM, as assayed by standard colorimetric assays. g, Filipin staining for cholesterol and 440 
Oil-Red-O staining (ORO) for neutral lipids in MCF10ATk1 cells treated with YM or FM 441 
(Fasudil+ML7). Inhibition of cholesterol and fatty acid synthesis with 10μM Cerivastatin (Ceri) or with 442 
15μM TOFA prevents accumulation. Here and through all figures, image acquisition settings were the 443 
same between controls and experimental samples. Scale bar 5μm. h, Accumulation of cholesterol and 444 
neutral lipids in MCF10ATk1 cells upon inhibition of RHO (C3 transferase transfection), non-muscle 445 
myosin II (20μM Blebbistatin) or by plating cells on soft (E≈0.5kPa) fibronectin-coated 446 
polyacrylamide hydrogels, compared to stiff (E≈15kPa) hydrogels. Scale bar 5μm. i, Transmission 447 
electron microscope pictures of MCF10ATk1 cells plated on stiff or soft hydrogel, with apparent lipid 448 
droplets (LD) and part of the nucleus (N). Scale bar 1μm. j,k, non-transformed human RPE1 (j) and 449 
primary mouse 3T3L1 (k) cells plated on stiff or soft hydrogels. Scale bar 5μm. The images in panels 450 
g-k are representative of at least two independent experiments with similar results; quantifications and 451 
n are provided in Supplementary Table 2. Data are mean and single points; unpaired two-tailed 452 
Student’s t-tests. 453 
 454 
Figure 2. ECM mechanical cues regulate SREBP1/2 target genes. 455 
a, Gene list enrichment analysis on probes significantly upregulated (mean fold>1.3 P<0.05) in 456 
microarrays of MCF10ATk1 cells treated with DMSO or Y27632+ML7 (YM) for 6 hours. The graphs 457 
display the 10 most significantly overrepresented gene sets for each of the indicated databases, 458 
analyzed with Enrichr and ranked according to combined score (x axis). Gene sets related to 459 
cholesterol, lipids and SREBP are highlighted in orange. b, Heatmap of SREBP target genes in 460 
microarrays of MCF10ATk1 cells treated as in a. Each column is an independent biological sample 461 
(n=3 for each condition); each line corresponds to a single gene probe indicated on the right. Blue and 462 
yellow extremes correspond to raw Z-scores of -2 and +2, respectively. c, LDLR-luciferase reporter 463 
assay for SREBP activity in MDA231 cells treated with YM or Fasudil+ML7 (FM). Mean expression 464 
in controls was set to 1, and other samples are relative to this (n≥6 independent biological samples per 465 
condition; unpaired Mann-Whitney tests). d, qPCR for established SREBP targets in RPE1 cells treated 466 
for 6 or 24 hours with DMSO, YM or FM (n≥4 independent biological samples per condition; multiple 467 
unpaired two-tailed Student’s t-tests). e-g, qPCR for established SREBP targets in MCF10ATk1 (e), 468 
RPE1 (f) or 3T3L1 (g) cells plated on stiff (E≈15kPa) or soft (E≈0.5kPa) ECM-coated hydrogels for 24 469 
hours (n≥4 independent biological samples per condition; multiple unpaired two-tailed Student’s t-470 
tests). In d-g data are relative to GAPDH levels; mean expression in controls (DMSO or stiff) were set 471 
to 1, and all other samples are relative to this. Data are mean and single points. 472 
 473 
Figure 3. ECM mechanical cues regulate lipid synthesis by controlling SREBP1/2 activation. 474 
a, qPCR analysis in MCF10ATk1 cells 48 hours after transfection with control siRNA (siCo.) or four 475 
independent mixes of siRNAs targeting SREBF1 and SREBF2 mRNAs (siSREBP A to D). b, qPCR 476 
analysis of established SREBP1/2 targets in MCF10ATk1 transfected as in a and treated with DMSO 477 
or YM for 24 hours. In a and b mRNA expression data are relative to GAPDH levels; mean expression 478 
levels in controls was set to 1, and all other samples are expressed relative to this (n≥4 independent 479 
biological samples per condition; unpaired Mann-Whitney tests). c, Cholesterol accumulation in 480 
MCF10ATk1 cells transfected with SREBP1/2 siRNA (siSREBP mixes A and B) and plated on soft 481 
hydrogels. Scale bar 5μm. Quantification and n is provided in Supplementary Table 2. d, 482 
Immunofluorescence for endogenous SREBP2 in MCF10ATk1 cells with inhibited ROCK/MLCK 483 
(YM), RHO (C3 plasmid transfection), MyosinII (Blebbistatin 10μM), or plated on soft hydrogels for 6 484 
hours. Cell contour in the YM 2h panel (dotted line) helps visualizing SREBP2 concentration at the 485 
Golgi apparatus. Scale bar 10μm. n>50 cells per condition. e, Western blotting for the mature form of 486 
endogenous SREBP1 and SREBP2 in MCF10ATk1 cells treated 4 hours with YM or FM. TEAD1 is a 487 
loading control for nuclear extracts. See also Supplementary Fig. 8. f, Immunofluorescence for 488 
endogenous SREBP2 in MCF10ATk1 cells treated 4 hours with YM in the presence of 100μg/ml 489 
cycloheximide (CHX). Scale bar 10μm. n>50 cells per condition. g, Western blotting on total extracts 490 
of MCF10ATk1 cells untreated (-), treated for 3 hours with 2μg/ml puromycin alone (puro) or with 491 
puromycin and 100μg/ml cycloheximide (CHX). Incorporation of the puromycin aminoacid analog 492 
into nascent proteins is used as control for efficient inhibition of protein synthesis. See also 493 
Supplementary Fig. 8. h, LDLR-luciferase in MDA231 cells. YM and FM activate endogenous 494 
SREBP, but have no additive effects in cells depleted of SREBP1/2 (siSREBP) and expressing a 495 
siRNA-insensitive, cleaved mature SREBP2 cDNA (caSREBP2). Mean expression in controls was set 496 
to 1, and other samples are relative to this (n≥4 independent biological samples per condition; unpaired 497 
Mann-Whitney tests). i, Heatmap of SREBP and YAP target levels in n=7 patient-matched soft normal 498 
skin vs. stiff keloid tissue. Each column represents -log2(keloid/skin) values for a single patient; each 499 
line is a single gene probe; genes ranked according to expression in patient #1. Selected gene names are 500 
indicated on the right; only the 60 most up- or downregulated genes (P<0.05) are included. All n values 501 
are pooled between independent experiments. The images in c-g are representative of at least two 502 
independent experiments with similar results. Data are mean and single points. 503 
 504 
Figure 4. ECM mechanical cues regulate SCAP accumulation to the Golgi apparatus. 505 
a, Co-localization of transfected MYC-tagged SCAP with a Golgi marker (GM130) in MCF10ATk1 506 
cells cultured 6 hours on soft hydrogels (E≈0.5kPa), treated 6 hours with Y27632+ML7 (YM) or 507 
transfected with the C3 RHO inhibitor. Scale bar 10μm. n>50 cells per condition. b, Co-localization of 508 
transfected MYC-SCAP with a Golgi marker (GFP-Rab6) in RPE1 cells treated 6 hours with YM. 509 
Scale bar 10μm. n>50 cells per condition. c, LDLR-luciferase in MDA231 cells transfected with 510 
control siRNA (siCo.), with two independent SCAP siRNA (siSCAP A and B), or treated with 30μM 511 
25-hydroxycholesterol (25OHC). d, LDLR-luciferase in MDA231 cells treated with the site-1 protease 512 
(S1P) inhibitor PF429242 (10μM). e, LDLR-luciferase in MDA231 cells transfected the C3 RHO 513 
inhibitor and treated as in c and d. In panels c-e, n≥4 independent biological samples per condition; 514 
mean expression in controls were set to 1, and all other samples are relative to this; data are mean and 515 
single points; unpaired Mann-Whitney tests. f, Human Pluripotent Stem Cells (hPSC) were dissociated 516 
and plated as single cells in the absence (DMSO) or presence of 10μM Y27632, without or with titrated 517 
doses of Cerivastatin (Ceri 25nM) and TOFA (75nM) for 24 hours, released in medium without 518 
inhibitors for 4 days, and stained for alkaline phosphatase to visualize self-renewing colonies. Lower 519 
panels: similar treatment on already-established colonies. Higher doses of Ceri/TOFA (10μM and 520 
15μM) inhibit also established colonies. g, hPSC plated as in f and treated with 1,25μM 25-521 
hydroxycholesterol. h, hPSC transfected with the indicated siRNAs and plated as single cells. The 522 
images in f-h are representative of at least two independent experiments with similar results; 523 
quantifications and n are provided in Supplementary Table 2. All n values are pooled between 524 
independent experiments. 525 
 526 
Figure 5. ECM mechanical cues regulate Lipin-1/ARF1 signaling. 527 
a,b, qPCR for SREBP target genes in MCF10ATk1 cells treated with DMSO or with 100μM 528 
Propranolol (Propra) to inhibit Lipin-1 phosphatidate phosphatase activity (a), or transfected with 529 
control (siCo.) and Lipin-1 siRNA (siLipin-1) (b). Data are relative to GAPDH levels; mean expression 530 
in controls was set to 1, and all other samples are relative to this (n≥4 independent biological samples 531 
per condition; multiple unpaired Student’s t-tests). c, LDLR-luciferase in MDA231 cells transfected 532 
with the indicated siRNA and treated with 100μM Propranolol (Propra). Mean expression in the control 533 
was set to 1, and all other samples are relative to this (n≥4 independent biological samples per 534 
condition; unpaired Mann-Whitney tests). d, Immunofluorescence for endogenous SREBP2 in 535 
MCF10ATk1 cells treated with Propranolol, transfected with Lipin-1 or COPI siRNA, or expressing 536 
dominant-negative ARF1-T31N-GFP (DN ARF1). Scale bar 10μm. n>50 cells per condition. e, Co-537 
localization of transfected MYC-SCAP with the GFP-Rab6 Golgi marker in RPE1 cells treated 6 hours 538 
with Propranolol, in cells transfected with control (siCo.), Lipin-1 or COPI siRNAs, or expressing 539 
dominant-negative ARF1-T31N (DN ARF1). Scale bar 10μm. n>50 cells per condition. f, Lipid 540 
staining in MCF10ATk1 cells treated for 24 hours with YM, with 100μM Propranolol, or transfected 541 
with Lipin-1 siRNA. Scale bar 5μm. Quantifications and n are provided in Supplementary Table 2. g, 542 
Western blotting for Lipin-1 levels in microsomal fractions from MCF10ATk1 cells treated 3 hours 543 
with DMSO or Y27632+ML7 (YM). Calreticulin (ER marker) and GM130 (Golgi marker) are loading 544 
controls. See also Supplementary Fig. 8. h, Co-localization of transfected GFP-PKD-KD with the 545 
GM130 Golgi marker in HEK293 cells treated for 30 min with YM, with 100μM Propranolol, or 546 
transfected with control (siCo.) and Lipin-1 siRNAs. Scale bar 10μm. Mean Pearson’s correlation 547 
coefficient and SD for co-localization is indicated above each panel (n≥10 cells were measured for 548 
each condition). i, GST-GGA3-PBD pulldown for GTP-bound active ARF1 (GTP-Arf1) and western 549 
blotting for ARF1 in the total extracts (Total Arf1). Cells were treated 3 hours with DMSO or YM. See 550 
also Supplementary Fig. 8. j, Co-localization of endogenous ARF1 with a Golgi marker (GM130) in 551 
MCF10ATk1 cells treated 6 hours with YM or Propranolol. Scale bar 10μm. Mean Pearson’s 552 
correlation coefficient and SD for co-localization is indicated above each panel (n≥10 cells were 553 
measured for each condition). The images in d-j are representative of at least two independent 554 
experiments with similar results. All n values are pooled between independent experiments. Data are 555 
mean and single points. 556 
 557 
Figure 6. Actomyosin contractility regulates SREBP through Lipin-1. 558 
a, Western blotting for transfected FLAG-tagged Lipin-1 in HEK293 cells treated with DMSO or YM 559 
for 6 hours. The 17S/A mutant is not phosphorylated and migrates faster than WT Lipin-1. GAPDH 560 
serves as loading control. See also Supplementary Fig. 8. b, Immunofluorescence for transfected 561 
FLAG-Lipin-1 in MCF10ATk1 cells treated 6 hours with YM, Blebbistatin, or plated on a soft 562 
hydrogel. Scale bar 10μm. n>50 cells per condition. c, Immunofluorescence for transfected wild-type 563 
(WT) or 17S/A FLAG-tagged Lipin-1 isoforms in RPE1 cells, treated with DMSO, YM or Torin1 564 
(500nM) for 6 hours. Fusion with the membrane-localization domain of Syntaxin5 tethers MB-Lipin-1 565 
to cytoplasmic membranes. Scale bar 10μm. n>50 cells per condition. Similar results were obtained 566 
with MB*-Lipin-1 (used in d) and in other cell lines. d, LDLR-luciferase (top) and FASN-luciferase 567 
(bottom) assays in MDA231 cells treated with the ROCK/MLCK inhibitor FM and transfected with 568 
wild-type (WT), membrane-tethered (MB and MB*) or 17S/A Lipin-1 isoforms. e, LDLR-luciferase 569 
(top) and FASN-luciferase (bottom) assays in MDA231 cells transfected with the C3 RHO inhibitor 570 
without or with membrane-tethered (MB) Lipin-1. In d and e, mean expression in the control was set to 571 
1, and all other samples are relative to this; n≥4 independent biological samples per condition; unpaired 572 
Mann-Whitney tests. f, MDA231 cells were transfected with WT-Lipin-1 or MB-Lipin-1 together with 573 
mCherry (RFP), treated with YM, and stained for cholesterol. n>30 cells per condition. Graph: cells 574 
were scored positive (+ve) for Filipin based on the presence/absence of cytoplasmic cholesterol 575 
accumulation. The images in a, b, c and f are representative of at least two independent experiments 576 
with similar results. All n values are pooled between independent experiments. Data are mean and 577 
single points. 578 
 579 
Figure 7. The Golgi apparatus responds to extracellular physical cues and intracellular force 580 
application. 581 
a, Co-localization of transfected MYC- SCAP with the GFP-Rab6 Golgi marker in RPE1 cells freely 582 
spreading on fibronectin-coated glass (Large) or plated on micropatterned fibronectin islands 583 
restraining cell area and inducing low F-actin tension (Small, 960μm2 or 490μm2). Scale bar 10μm. 584 
n>30 cells per condition. b, Golgi rheology was measured in RPE1 cells plated as in a. GFP-Rab6-585 
positive Golgi membranes were pushed towards a cytoplasmic bead immobilized by an optical trap in a 586 
series of five 0.5µm steps in 1 min (see Supplementary Fig. 7a and Methods). The graph shows the 587 
averaged displacements of the bead during the first step (see Supplementary Fig. 7b for the complete 588 
graph). Green line: large unconfined cells, conditions of high tension (n=39 cells). The Golgi 589 
microenvironment displays a visco-elastic behavior as the bead is first maximally displaced (Bead Step 590 
Amplitude), and then slowly relaxes back due to attraction from the optical trap. Orange and Red lines: 591 
micropatterned small ECM (n=28, 21 cells). Gray shadows: s.e.m. error bars. A smaller displacement 592 
and a faster relaxation of the bead indicate a lower rigidity of the Golgi apparatus. c, The Rigidity 593 
Index (RI) measures the friction opposed by the Golgi microenvironment on the bead, with lower 594 
values indicating a softer microenvironment. The Bead Step Amplitude corresponds to the average 595 
displacement of the bead after each step, with lower values indicating a softer microenvironment. The 596 
Ejection Frequency measures the relative frequency of experiments in which the bead falls off the 597 
optical trap, which is increased with the resisting friction forces applied on the bead by the Golgi. d, 598 
Time-lapse confocal images of a representative RPE1 cell transfected with the GFP-PKD-KD 599 
diacylglycerol sensor and with a Golgi-localized mCherry. A 2μm-diameter cytoplasmic bead (yellow 600 
dotted line) was immobilized by an optical trap in the proximity of the Golgi apparatus (t=0) and then 601 
pushed every 5 min. towards the Golgi (white arrow: direction of the compressive constraint). e, 602 
Normalized intensity of the PKD-KD signal before and after application of force (n=19 cells). In the 603 
control the bead was moved away from the Golgi towards the cytoplasm (n=18 cells). The images in a 604 
and d are representative of at least two independent experiments with similar results. All n values are 605 
pooled between independent experiments. Data are mean and s.e.m.; two-tailed unpaired Student’s t-606 
tests. 607 
 608 
Methods 1 
 2 
Reagents. Plasmids encoding for SCAP-MYC, HA-S1P, HA-S2P were from Y. Chen (SIBS 3 
Shanghai), Perilipin3-RFP from L. Scorrano (UniPd), kinase-dead GFP-PKD1-K612W from A. 4 
Hausser (UniStuttgart), ARF1-T31N-GFP from A. DeMatteis (TIGEM Naples), KDEL-mCherry from 5 
E. Greotti (UniPd), GFP-OSBP from N. Ridgway (UniGlasgow). Addgene plasmids: FASN-lux #8890; 6 
LDLR-lux #14940; 8XGTIIC-lux #34615; NF2 #19701; CMV-Luc2P_ARE #62857; constitutive-7 
active FLAG-SREBP2 #26807; FLAG-Lipin-1 WT #32005 and 17S/A #32007; mCherry-8 
Golgi(B4GALT1) #55052. Full length SREBP1 and SREBP2 were subcloned from Addgene plasmids 9 
#32017 and #32018. ER/Golgi membrane-tethered Lipin-1 isoforms were obtained by in-frame fusion 10 
of the Syntaxin5 delta220 or TMD fragments53,54 to FLAG-Lipin-1 WT and have been deposited as 11 
Addgene plasmids #120277 and #120278. SUMOylation (K616/646A) and acetylation (K476/646A) 12 
FLAG-Lipin-1 mutants were obtained by targeted mutagenesis. All plasmids were sequence-verified 13 
before use and transfected as endotoxin-free maxi preps. 14 
Small molecule inhibitors were: Y27632 (Axon 1683, 20 microM, 10 microM on hPSC); 15 
Fasudil/HA1077 (SantaCruzBiotechnology sc358231, 20 microM); ML7 (Sigma I2764, 20 microM); 16 
Blebbistatin (Sigma B0560, 20 microM); Propranolol (Sigma P0884, 100 microM); Cycloheximide 17 
(Sigma C1988, 100 microg/ml); TOFA (Sigma T6575, 15 microM, 75 nanoM on hPSC); Cerivastatin 18 
(Sigma SML0005, 10 microM, 25 nanoM on hPSC); 25-hydroxy-cholesterol (Sigma SML2042, 30 19 
microM, 1.25 microM on hPSC); U18666A (SantaCruzBioTechnology sc203306, 3 microM); 20 
PF429242 (Sigma SML0667, 10 microM); Z-VAD-FMK (Sigma V116, 30 microM); Torin1 (Axon 21 
1833, 500 nanoM); MG132 (Sigma C2211, 10 microM); MG115 (Sigma C6706, 10 microM). 22 
siRNAs were selected among FlexiTube GeneSolution 4 siRNA sets (Qiagen) and reordered 23 
after validation as dTdT-overhanging 19nt RNA duplexes (Thermo). siRNA sequences: SREBF1a 24 
CGGAGAAGCUGCCUAUCAA; SREBF1b GCGCACUGCUGUCCACAAA; SREBF1c 25 
GCGCACUGCUGUCCACAAA; SREBF1d ACAGCAACCAGAAACTCAA; SREBF2a 26 
GCAGUGUCCUGUCAUUCGA; SREBF2b GCAAUUUGUCAGUAAUCAA; SREBF2c 27 
GGCCAUUGAUUACAUCAAA; SREBF2d CGAUAUCGCUCCUCCAUCA; SCAPa 28 
GGAAGAUCGACAUGGUCAA; SCAPb GGCCGACGCUCUUCAGCUA; LPIN1 29 
GUUCGGAUACCUUCAGUAA; YAP CUGGUCAGAGAUACUUCUU; TAZ 30 
AGGUACUUCCUCAAUCACA; AMPKa1/2 mixes a and b see Ref.55; COPIa 31 
GAUUUACCGAGGAGCAUUA; COPIb GGAUCGCUUGAUAGAAUUA; AllStars Negative 32 
Control (Qiagen) sequence not available – proprietary information. 33 
 34 
Cell cultures. MCF10A, MCF10ATk1 MCF10ATk1 pBABE mTAZ 4SA were cultured in 35 
DMEM/F12 5%HS Insulin (Sigma) Cholera Toxin (Sigma) hEGF (Peprotech) and Hydrocortisone 36 
(Sigma). GFP-Rab6 and parental RPE1 in DMEM/F12 10%FBS (neomycin for GFP-Rab6). MDA-37 
MB-231 in DMEM/F12 10%FBS. HEK293 in DMEM 10%FBS. WI-38 in MEM 10%FBS 5% oxygen. 38 
3T3-L1 in DMEM 10%FBS 5% oxygen. H9 hPSC in E8 medium (DMEM/F12, NaHCO3, Insulin, 39 
Selenium, Transferrin, L-ascorbic acid, FGF2, TGFb1) 5% oxygen. WT and AMPKa1/2-/- MEFs in 40 
DMEM 20%FBS. Glutamine was freshly added to a final concentration of 20mM to all media. General 41 
media, serum and supplements were from Thermo. Cytokines from Sigma and Peprotech. All cell lines 42 
were routinely tested with ATCC Universal Mycoplasma Detection kit to exclude contaminations. 43 
Cells for immunofluorescence in a stiff microenvironment were plated on fibronectin-coated glass 44 
coverslips. Stiff (E≈15KPa) and soft (E≈0.5KPa) fibronectin-coated polyacrylamide hydrogels were 45 
assembled in-house by standard protocols. Annular-shaped micropatterns (25 or 35µm diameter, 5µm 46 
line thickness) were printed on PEG-coated glass coverslips by deep UV photolithography and coated 47 
with 50μg/ml fibronectin supplemented with 20μg/ml Alexa647-fibrinogen (Sigma). hPSC were 48 
dissociated with Tryple (Thermo) and plated as single cells (2500 cells/2cm2 well) in the presence or 49 
absence of the indicated small molecules for 24 hours; medium was then changed and cells were left 50 
growing for 4-5 days, until the appearance of macroscopic colonies. Treatment of colonies was done on 51 
colonies grown from single cells as above, and then treating for 24 hours. Cell transfections were 52 
carried out with Transit-LT1 (MirusBio) or with Lipofectamine RNAi-MAX (Thermo). 53 
 54 
Antibodies, immunofluorescence and stains. See Supplementary Table 1 for catalog numbers, 55 
dilutions and validations. For the SREBP2 antibodies, independent lots were used with consistent 56 
results. Immunofluorescence was performed as in56 with minor modifications: 10min 1.5mg/ml glycine 57 
in PBS before permeabilization to reduce background; blocking in 1-2% BSA. Images were acquired 58 
sequentially with a Zeiss LSN700 or a Leica SP5 confocal microscope equipped with a CCD camera 59 
using ZEN 2 or Leica LAS AF softwares. Typical acquisition settings for IF were: image size 60 
1024x1024 pixels; acquisition mode xyz; pixel size 0.15μm; image depth 8 bits; acquisition speed 5/10, 61 
with average 2; Plan-Apochromat 63x/1.40 oil DIC M27 objective. For multichannel acquisitions, we 62 
used a main beam splitter 405/488/555/639. Raw images (saved in .czi or .lif formats) were opened in 63 
ImageJ and saved in exportable formats. If needed, colors were changed (e.g. red to green) with 64 
Photoshop CC. 65 
Oil Red-O staining (Sigma) was carried out after fixation, in 60% v/v isopropanol/water. C11-66 
Bodipy581/591 (Thermo) were incubated 15min with cells before FACS analysis. Filipin staining was 67 
acquired using a UV filter set (340/380nm excitation, 40nm dichroic, 430nm long pass filter) by 68 
prefocusing cells based on TOTO3 nuclear counterstain (633/647nm) and then acquiring the UV 69 
channel without prior observation to avoid photobleaching. Typical acquisition settings for Filipin 70 
were: image size 1024x1024 pixels; acquisition mode xyz; pixel size 0.15μm; image depth 8 bits; 71 
acquisition speed 5/10, with average 2; Plan-Apochromat 63x/1.40 oil DIC M27 objective. Pictures 72 
were always taken by using the same acquisition conditions between all different experimental 73 
samples; panels are representative pictures based on at least two independent experiments. 74 
Quantifications and n are provided in Supplementary Table 2. 75 
Alkaline phosphatase staining was Leukocyte AP kit (Sigma). Panels shown are representative 76 
pictures of one biological replicate of one experiment; each experiment was repeated three times 77 
independently. Quantifications and n are provided in Supplementary Table 2. 78 
 79 
Cell fractionation, western blotting and pulldown. Nuclear extracts and microsomes were obtained 80 
by resuspending cells in lysis buffer (250mM Sucrose, 10mM Triethanolamine pH=7.4, 10mM 81 
AceticAcid, 1mM EDTA, 10mM KCl) and passing cells 8 times (i.e. complete lysis at the microscope) 82 
through an Isobiotec Cell Homogenizer with a 6micron clearance sphere. Lysates were centrifuged at 83 
800rcf to isolate nuclei, and then at 100.000rcf to isolate microsomes. Western blotting was performed 84 
as in Ref57; in Fig. 3e and Supplementary Fig. 3h cells were incubated with 10microM MG132/MG115 85 
proteasome inhibitors during treatment to prevent degradation of cleaved SREBPs.  Active GTP-bound 86 
ARF1 pulldown was performed with a commercial kit following the manifacturer’s intructions 87 
(Cytoskeleton Inc. BK032). 88 
 89 
Gene expression studies. Luciferase assays were performed in MDA-MB-231 cells as in 90 
Ref.55. For qPCR, total RNA was isolated using commercial kits with DNAse treatment (Qiagen, 91 
Norgen). cDNA synthesis was carried out with M-MLV Reverse Trascriptase (Thermo) and oligo-dT 92 
primers. qPCR reactions were assembled with FastStart SYBR Green Master Mix (Roche) and run on a 93 
QuantStudio6 thermal cycler (Thermo). Gene expression levels for each biological sample was 94 
quantified as the mean between three technical replicates; GAPDH expression levels were used to 95 
normalize gene expression between samples, based on the 2−ΔΔCt method. 96 
 Sequences of primers: ACSS2 For GTT GAC TCC CCT TCC TGG TG, Rev CTT CCA ACT 97 
CTT CCC CGG AC; CTGF AGG AGT GGG TGT GTG ACG Rev ACC AGG CAG TTG GCT CTA 98 
ATC; DHCR7 For CCG CCC AGC TCT ATA CCT TG, Rev ACT TGT TCA CAA CCC CTG CA; 99 
FASN For GGA GGA GTG TAA ACA GCG CT, Rev TTG GCA AAC ACA CCC TCC TT; HMGCR 100 
For TGC AGC AAA CAT TGT CAC CG, Rev CAC CAC CCA CCG TTC CTA TC; HMGCS1 For 101 
ACA CAA GAT GCT ACA CCG GG, Rev ATG GGT GTC CTC TCT GAG CT; LDLR For AAG 102 
GAC ACA GCA CAC AAC CA, Rev AAA GGA AGA CGA GGA GCA CG; LPN1 For ACA TGG 103 
ATC CTG AAG TGG CG, Rev GAG ATG GCG ATG GAA GGG AG; SQLE For AGG CGC AGA 104 
AAA GGA ACC AA, Rev GCC AGC TCC CAC GAT GAT AA; SCD For CCA CTT GCT GCA 105 
GGA CGA TA, Rev CCA AGT AGA GGG GCA TCG TC; SREBF1 For CGT TTC TTC GTG GAT 106 
GGG GA, Rev CCC GGA ATA GCT GAG TCA CC; SREBF2 For GGG CTG GTT TGA CTG GAT 107 
GA, Rev AGA TCT GCC TGT TTC CGG TG; SCAP For CAG CAG CAA CAC AGT GAC CT, Rev 108 
TAT GGT CTT GGC TCC CTG TC; GAPDH For CTC CTG CAC CAC CAA CTG CT, Rev GGG 109 
CCA TCC ACA GTC TTC TG; COPI For AGT ACA GCC TGA TGA CCC CA, Rev TGC TGC CTC 110 
TTT CCT CTG TG; AMPKa1 For CTT GCC AAA GGA GTG ATT CAG ATG C, Rev AGG TCA 111 
ACA GGA GAA GAG TCA AGT GT; AMPKa2 For AGC GTT CCT GTT CTG CTG CT, Rev TCC 112 
ATG GTG TGA CTG CCC AG. 113 
Microarray probe synthesis, hybridization and detection were performed at CMB Trieste on 114 
HumanHT-12 v4 Expression BeadChips with an Illumina Hiscan system. Data analyses were 115 
performed in R (version 3.0.2) using Bioconductor libraries (BioC 2.13) and R statistical packages. 116 
Probe level signals were converted to expression values using robust multi-array average procedure 117 
RMA58 of Bioconductor Affymetrix package. Differentially expressed genes were identified using 118 
Significance Analysis of Microarray (SAM) algorithm coded in the same R package59. In SAM, we 119 
estimated the percentage of false-positive predictions (i.e., false discovery rate, FDR) with 100 120 
permutations. Genes activated or inhibited upon YM treatment and used for Gene List Enrichment 121 
Analysis were filtered based on P-value<0.05 and fold change>1.3. Gene List Enrichment Analysis 122 
was performed with Enrichr60. SREBP target genes were defined based on Ref.61,62. 123 
 124 
Metabolomics and metabolic analyses. Large-scale metabolic analysis (global metabolomics) and 125 
Principal Component Analysis of the results was carried out by Metabolon Inc. Mechanosensitive 126 
MCF10Tk1 cells56 were washed once in warm 1XPBS, and metabolites were extracted 5 min at RT on 127 
15cm plates with 80% v/v Methanol/Water extraction buffer with internal standards. We harvested 128 
cells on plate to specifically avoid alteration of actin tension and of metabolism due to cell detachment. 129 
Metabolites were normalized to protein content. This analysis did not focus on triglyceride content. 130 
Clustering of selected lipid metabolites (fold change>2.5; p-value<0.05) shown in Supplementary Fig. 131 
1e was carried out with Heatmapper. 132 
Targeted lipidomic analysis was carried out on MCF10Tk1 cells lysed in 1:1 v/v 133 
MeOH/Acetonitrile extraction buffer by tissue lyser and spun at 20,000g for 5 min at 4°C. Supernatant 134 
were then passed through a regenerated cellulose filter, dried and resuspended in 100µl of MeOH. 135 
For the quantification of the different phospholipid species the liquid chromatography tandem 136 
mass spectrometry LC-MS/MS analysis was performed on API-4000 triple quadrupole mass 137 
spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS autosampler 138 
(PAL System). The identity of the different phospholipid families was confirmed using pure standards, 139 
namely one for each family. Methanolic extracts were analyzed by a 5 minutes run in both positive and 140 
negative ion mode with a 275 multiple reaction monitoring (MRM) transitions in positive mode and 92 141 
MRM transitions in negative mode. Quantification of different phospholipids in positive ion mode was 142 
performed using a Synergi 4μ Hydro-RP (50mm x 2.0mm, 4μm; Phenomenex) and in negative ion 143 
mode using Cyano-phase LUNA column (50mm x 4.6mm, 5μm; Phenomenex). The mobile phase for 144 
positive ion mode was 0.1 % formic acid in MeOH and 5 mM ammonium acetate pH 7 in MeOH for 145 
negative ion mode both with a with a flow rate of 500μl/min. MultiQuant™ software version 3.0.2 was 146 
used for data analysis and peak review of chromatograms. Semi-quantitative evaluation of different 147 
phospholipids was performed based on external standards, then data were normalized on protein 148 
content assessed by BCA method. 149 
For the quantification of the different diacylglycerol and triacylglycerol species the liquid 150 
chromatography tandem mass spectrometry LC-MS/MS analysis was performed on API-4000 triple 151 
quadrupole mass spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS 152 
autosampler (PAL System). Methanolic extracts were dried under nitrogen and resuspended in 100µl of 153 
65% Acetonitrile/30% isopropanol/5% water. Samples were then analyzed by a 10 minutes run in 154 
positive ion mode with a 92 multiple reaction monitoring (MRM) transitions. Quantification of 155 
different diacylglycerols and triacylglycerols was performed using a XBridge™ C-18 (100mm x 156 
2.1mm, 3.5μm; Waters). Column temperature was set at 55°C. The mobile phases were phase A: 40% 157 
acetonitrile, 0.1 % formic acid and 10 mM ammonium acetate in water; phase B: isopropanol 90%, 158 
acetonitrile 10%, 0.1 % formic acid and 10 mM ammonium acetate. T0: 55%A; T2min: 55%A; T4min: 159 
3%A; T7min: 3%A; T7.1min: 55%A; T10min: 55%A; with a flow rate of 260μl/min. MultiQuant™ software 160 
version 3.0.2 was used for data analysis and peak review of chromatograms. Semi-quantitative 161 
evaluation of different diacylglycerols and triacylglycerols was performed based on external standards, 162 
then data were normalized on protein content assessed by BCA method. 163 
For isotopolog analysis, cells were exposed to 2.5mM [13C2]acetate (Sigma 282014) for 24h. 164 
After removing media, cells were washed in ice-cold PBS. Lipid extraction was performed by adding 165 
500μl of MeOH/ACN (1:1 v/v), and then 2.5ml of chloroform-MeOH (1:1, v/v). Total FAs were 166 
obtained by acid hydrolysis adding 1.25ml of HCl 1M and 1.25ml of MeOH. After leaving samples 1h 167 
in agitation at 210 rpm, 2.5ml of chloroform-water (1:1, v/v) were added to the mixture and the lower 168 
organic phase was collected, split, transferred into tubes, and dried under nitrogen flow. The residue 169 
was resuspended in MeOH/H2O (1:1, v/v) and used for total FA analysis. Sample were analyzed by and 170 
API 4000 mass spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS 171 
autosampler (PAL System). The gradient (flow rate 0.5 ml/min) was as follows: T0: 20% A, T20: 1% 172 
A, T25: 1% A, T25.1: 20% A, T30: 20% A, where A: acetic acid 15mM and N-ethylisopropylamine 173 
10mM in H2O:MeOH 97:3 and B: MeOH. The Hypersil GOLDTM column (C8 100mm x 3mm, 3μm; 174 
Thermo-Scientific) was maintained at 40°C for all the analysis. 175 
For the quantification of free and total fatty acids and cholesterol levels, we used an aliquot of 176 
extracts described above and commercial kits (Sigma MAK044 and MAK043) following the 177 
instructions. 178 
 179 
Intracellular optical micromanipulation, microrheological measurements and analysis. The set-up 180 
combining optical trapping and confocal imaging was described previously47. Briefly, red fluorescent 181 
580/605nm 2μm diameter latex beads (Thermo F88265) were endocytosed overnight in RPE1 cells 182 
stably expressing the Golgi marker GFP-Rab6. The incubation time and bead concentration were 183 
adjusted so that cells typically contained one or two beads before optical micromanipulation. Cells 184 
were plated on 18mm diameter coverslips uniformly coated with fibronectin, or with annular-shaped 185 
adhesive fluorescent micropatterns of different diameters (25 or 35 μm), during 6 hours. Non-adherent 186 
cells were washed off by rinsing with culture medium. The coverslip was then mounted in a Ludin 187 
chamber and the culture medium was supplemented with 20mM Hepes prior to the experiment. 188 
Force was applied on GFP-positive Golgi membranes by first trapping a bead located close to 189 
the Golgi apparatus and then displacing the microscope stage in order to push the organelle against the 190 
trapped bead. Trapping was not possible on polyacrilamide hydrogels because of the excessive distance 191 
between lens and cells in this set-up. The applied force F was deduced from the bead displacement 192 
relative to the trap center Δx after calibration of the trap stiffness k୲୰ୟ୮	using F = k୲୰ୟ୮	Δx with 193 
k୲୰ୟ୮ = 280	pN/μm. The output power of the infra-red laser at the objective aperture was 150 mW. 194 
Stage displacement was performed using a nanopositioning piezo-stage (Nanobio 200, Mad City Labs) 195 
controlled by the NanoRoute3D software (Mad City Labs). The stage displacement consisted in five 196 
consecutive 0.5μm steps with a 10s pause between each step to allow visco-elastic relaxation of the 197 
bead position towards the trap center. The total duration of optical trapping was limited to 1 min for a 198 
given cell to ensure cell viability. 199 
To characterize the rigidity of the microenvironment surrounding the bead, we used a 200 
phenomenological analysis of the relaxation curves as in47,63 to measure three parameters: the 201 
frequency of bead ejection, the bead step amplitude and the rigidity index. Qualitatively, in a low 202 
rigidity microenvironment, friction on the bead is low and the bead does not move much from the trap 203 
center during the step displacement and relaxes rapidly towards the trap center. In a rigid 204 
microenvironment, the bead experiences a high friction and its initial displacement is bigger and closer 205 
to the step displacement (0.5µm) and the relaxation is slower. If the force acting on the bead is too 206 
large (typically above 300-400pN), the bead falls off the trap and subsequently follows the 207 
displacement of the stage. We termed such events ‘ejections’ and scored their frequency (defined as the 208 
ratio between the number of experiments in which ejection occurred and the total number of 209 
experiments) and the step at which ejection occurred. The bead step amplitude Xୠ corresponds to the 210 
displacement of the bead after a 0.5µm step of the piezo-stage. Values of Xୠ close to 0.5µm indicate a 211 
high rigidity of the bead microenvironment. Lower values are indicative of softer microenvironments. 212 
The rigidity index is defined as 213 
ܴܫ = 	
׬ ݔ௕(ݐ)݀ݐ௧೔ା்௧೔
׬ ݔ௦(ݐ)݀ݐ௧೔ା்௧೔
=
׬ ݔ௕(ݐ)݀ݐ௧೔ା்௧೔
ܺ௦ܶ  
where t୧ is the time when the i୲୦ 0.5 μm step displacement of the piezo-stage occurs, xୠ and xୱ are 214 
respectively the displacement of the bead relative to the trap center and the displacement of the piezo-215 
stage, Xୱ = 0.5μm is the amplitude of the piezo-stage step and T = 10s is the duration of the step. The 216 
rigidity index RI	is a phenomenological parameter which allows us to compare the rigidity of the 217 
microenvironment surrounding the bead in various conditions. The value of RI	falls between 0 (the 218 
microenvironment does not exert any friction on the bead) and 1 (the microenvironment is not 219 
deformable). The values of RI	for each step displacement were averaged. 220 
To measure GFP-PKD-KD recruitment upon force application, cells were plated at day 1 in a 221 
12-well plate to reach around 75% confluence on day 2. At day 2, cells were transfected with GFP-222 
PKD-KD and mCherry-Golgi(B4GALT1) plasmids. At the end of day 2, the cells were incubated with 223 
2μm diameter fluorescent beads overnight. At day 3, cells were transferred to fibronectin-coated 224 
coverslips for the experiment. The evolution of normalized intensity of GFP-PKD-KD in the region of 225 
the Golgi apparatus, visualized by the mCherry-Golgi marker, was monitored after application of a 226 
mechanical constraint exerted by internalized beads trapped with optical tweezers. A bead located near 227 
the Golgi apparatus was selected in a cell expressing GFP-PKD-KD and the mCherry-Golgi marker. A 228 
first image was taken at t=0min. The bead was then trapped with the optical tweezers and the 229 
microscope stage manually displaced to bring the Golgi apparatus in contact with the bead and apply a 230 
compressive constraint on the Golgi apparatus during 1 min. The same protocol was repeated every 231 
5min until t=30min. The duration of the compressive constraint was reduced to 30s after t=10min to 232 
avoid cellular damage due to prolonged laser exposure. As a control, the same protocol was used but 233 
the microscope stage was displaced in order to move the bead away from the Golgi apparatus. 234 
To quantify the fluorescence intensity of GFP-PKD-KD in each of the seven images taken every 235 
5 minutes, the Golgi apparatus was delimited using the mCherry Golgi marker. The total intensities of 236 
the mCherry Golgi marker (I୰) and of GFP-PKD-Kd (I୥) were measured as well as the mean intensity 237 
of the background for each channel (〈I୰	ୠୟୡ୩〉 for the mCherry Golgi marker and 〈I୥	ୠୟୡ୩〉 for GFP-PKD-238 
KD) and the area of the Golgi apparatus Aୋ୭୪୥୧. The total intensity of the background in the Golgi 239 
apparatus region for each channel was then estimated by multiplying the mean background intensity by 240 
the Golgi area: 241 
I୰	ୠୟୡ୩ = Aୋ୭୪୥୧	. 〈I୰	ୠୟୡ୩〉 
I୥	ୠୟୡ୩ = Aୋ୭୪୥୧	. 〈I୥	ୠୟୡ୩〉 
The fluorescence intensity of GFP-PKD-KD was normalized by the fluorescence intensity of 242 
the mCherry Golgi marker: 243 
I = 	 I୥ − I୥	ୠୟୡ୩	I୰ − I୰	ୠୟୡ୩  
to account for slight changes in the imaging plane from one image to the next. The relative 244 
temporal variations of the GFP-PKD-KD fluorescence were obtained by normalizing the intensity I 245 
measured from each image taken every 5 minutes by its initial value I଴: I(t) = I/I଴. 246 
 247 
Statistics and Reproducibility. All data are based on independent experiments with independent 248 
biological replicates, except for metabolomics and microarrays that were based on independent 249 
biological replicates harvested in a single experiment. Experimental repetitions were carried out by 250 
thawing a new aliquot of cells, deriving from the original stock. Key data were independently 251 
replicated by two different operators, across different cell lines, and with independent techniques 252 
providing coherent results. All n values are pooled between independent experiments. Data are 253 
presented as mean and single points, or mean and standard error of the mean (s.e.m.) as indicated in the 254 
figure legends. Significance tests were unpaired non-parametric Mann-Whitney tests, unpaired two-255 
tailed Student’s t-tests, multiple unpaired two-tailed Student’s t-tests with Holm-Sidak correction (for 256 
analysis of multiple qPCR markers), or Welch’s two sample t-tests (for global metabolomics). t-tests 257 
have been performed under the reasonable assumption that values follow a normal distribution and 258 
have similar variance. 259 
 260 
Code availability 261 
No custom codes were used in this study. All other codes are indicated in the appropriate methods 262 
sections and references. 263 
 264 
Data availability. Microarray, metabolomics and targeted lipidomics data have been deposited (GEO 265 
database GSE107275 and Figshare database 10.6084/m9.figshare.7338764). Source data for Figs. 1-7 266 
and Supplementary Figs. 1-7 have been provided in Supplementary Table 2. All other data supporting 267 
the findings of this study are available from the corresponding author on reasonable request. 268 
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keloid scars vs. normal skin 
1Sv1C 4Dv4C 2Sv2C 9Dv9C 3Sv3C 8Dv8C 5Dv5C
ALPK2 4 ,35 3,7 5 2,84 1 ,60 4,1 9 3,8 9 3 ,81
COL12A1 4 ,32 4 ,63 3,53 2 ,86 4 ,2 5 2,9 4 3 ,96
COL8A1 4 ,21 4 ,70 4,30 4 ,07 4 ,5 3 3,3 4 3 ,60
SPARC 4 ,05 5 ,15 3,19 1 ,94 4 ,2 2 2,6 1 4 ,38
COL1A1 3 ,95 4 ,57 3,07 2 ,19 4 ,3 3 2,8 7 3 ,82
CDH11 3 ,66 3 ,93 3,43 2 ,77 3 ,8 4 2,6 5 3 ,20
LRRN1 3 ,44 3 ,64 3,57 3 ,16 4 ,1 9 2,8 6 3 ,13
RFPL1 3 ,41 3 ,11 3,17 1 ,85 4 ,0 2 3,9 1 3 ,86
FN1 3 ,23 3 ,52 3,12 2 ,46 3 ,5 7 2,3 5 2 ,85
LOXL2 3 ,21 4 ,28 3,69 3 ,08 3 ,9 2 2,8 5 3 ,06
KDELR3 3 ,09 3 ,40 2,04 2 ,07 3 ,4 9 2,2 5 3 ,52
ST6GAL2 2 ,92 3 ,03 3,55 1 ,01 3 ,7 4 0,7 1 4 ,14
ODZ3 2 ,92 3,1 2 2,82 1 ,86 3 ,0 0 1,6 2 2 ,34
FLJ14213 2 ,82 2,5 4 2,32 1 ,92 2 ,9 0 1,7 0 2 ,45
MFAP5 2 ,76 4 ,18 1,11 1 ,57 2 ,7 3 1,9 9 2 ,88
PLOD2 2 ,68 3 ,81 3,00 2 ,40 2 ,6 0 2,1 1 2 ,44
PXDN 2 ,62 3 ,51 2,16 2 ,20 2 ,8 7 2,3 2 2 ,63
VCAN 2 ,61 4 ,18 2,50 2 ,24 2 ,7 8 2,0 9 2 ,94
LOX 2 ,58 3 ,34 1,25 0 ,78 2 ,1 8 1,2 4 2 ,50
TMEFF1 2 ,46 3,2 1 2,99 1 ,79 3 ,5 0 2,5 9 1 ,73
FBN1 2 ,40 3 ,74 1,43 1 ,90 2 ,8 8 1,9 5 3 ,24
KIAA0802 2 ,39 2 ,62 1,54 1 ,37 1 ,7 1 1,84 1 ,94
SGCD 2 ,27 2 ,79 1,67 1 ,62 2,0 4 1,5 4 1 ,94
FLJ42709 2 ,26 2,0 8 1,17 0 ,84 3 ,6 2 0,5 2 1 ,42
SERPINH1 2 ,23 3 ,60 1,24 1 ,67 2 ,6 0 1,5 2 2 ,15
RHOBTB1 2 ,22 2 ,57 1,57 1 ,15 2 ,1 8 1,3 5 1 ,96
MARCKS 2 ,13 2 ,42 2,10 1 ,12 2 ,1 2 1,2 6 2 ,03
TRPC3 2 ,03 2 ,98 1,96 1 ,58 2 ,1 2 1,2 6 1 ,55
RRBP1 2 ,02 2 ,28 1,46 1 ,48 2 ,1 5 1,5 1 2 ,37
TNNT3 1 ,99 1 ,60 0,79 0 ,85 1 ,0 1 0,7 2 0 ,77
FSTL1 1 ,98 2 ,97 1,11 1 ,22 2,2 3 1,5 6 2 ,70
FUT8 1 ,98 2 ,10 1,39 1 ,47 1 ,4 9 1,3 5 1 ,81
CDH2 1 ,96 4 ,58 2,04 2 ,86 2 ,5 4 2,9 0 3 ,08
MAGED1 1 ,96 1 ,87 1,36 1 ,36 2 ,1 3 1,1 8 1 ,75
BICC1 1 ,95 2 ,15 1,47 0 ,89 2 ,1 4 1,3 3 1 ,31
PRSS23 1 ,94 3,1 5 1,42 2 ,24 2 ,2 3 1,6 2 1 ,86
CALU 1 ,90 2 ,82 1,55 1 ,71 2 ,3 0 1,5 8 2 ,23
FZD2 1 ,89 2,1 2 1,42 1 ,26 2 ,1 7 1,4 6 1 ,17
SERPINE1 1 ,79 1 ,61 2,57 1 ,55 2 ,2 4 1,3 6 2 ,45
NR2F1 1 ,79 1 ,90 1,06 0 ,67 1 ,3 8 0,7 7 1 ,68
ARHGAP28 1 ,78 2,4 2 1,75 1 ,38 2 ,0 6 1,2 8 2 ,09
GCNT1 1 ,77 1 ,24 1,19 0 ,79 1 ,4 9 0,9 5 2 ,18
TMEM119 1 ,71 2 ,15 0,73 1 ,75 1,5 9 1,1 8 1 ,98
INHBA 1 ,70 2 ,45 1,70 1 ,98 2 ,5 8 1,2 2 1 ,37
RAB23 1 ,69 2,4 3 1,69 1 ,63 2 ,5 5 1,7 7 1 ,78
KHDRBS3 1 ,68 1 ,85 1,01 0 ,96 1 ,4 0 1,4 6 1 ,46
ITGB5 1 ,68 1,2 5 0,85 0 ,96 1,4 3 1,0 3 1 ,83
ZEB1 1 ,68 1 ,86 1,09 0 ,57 1 ,0 1 0,8 6 1 ,26
IGFBP3 1 ,64 1 ,68 1,14 1 ,04 0 ,4 1 0,73 0 ,98
PDLIM7 1 ,64 2 ,99 0,73 0 ,57 1 ,7 7 1,4 2 1 ,15
PRKCDBP 1 ,61 1 ,57 0,94 0 ,84 1 ,6 5 1,0 8 1 ,40
STC2 1 ,60 3 ,08 0,56 0 ,98 2,1 7 1,1 6 2 ,24
KDELR2 1 ,58 1 ,59 1,14 0 ,47 1 ,5 9 0,8 4 1 ,68
WNT5A 1 ,57 1 ,65 1,23 0 ,93 1 ,7 1 0,8 6 1 ,07
CTGF 1 ,55 3 ,87 1,72 2 ,70 1 ,7 5 2,5 4 3 ,41
NAV3 1 ,54 1 ,02 0,66 0 ,35 0 ,8 2 0,6 1 1 ,45
PRKD1 1 ,52 1 ,39 1,11 0 ,84 1 ,7 6 0,9 1 1 ,17
TXNDC5 1 ,50 1 ,94 1,16 0 ,89 1 ,5 7 1,1 8 1 ,56
FAM110B 1 ,49 1 ,27 1,21 0 ,67 1 ,2 2 0,9 2 0 ,71
PDGFRL 1 ,48 1 ,79 0,97 0 ,38 1 ,3 0 1,1 5 2 ,09
NAV1 1 ,46 1 ,40 1,11 1 ,04 1 ,3 0 0,7 0 2 ,11
BPGM 1 ,45 1 ,13 1,32 0 ,97 1 ,5 0 0,9 5 0 ,97
TMEM2 1 ,38 1 ,60 0,84 0 ,91 1,1 2 0,8 5 1 ,03
CNN3 1 ,36 1 ,98 1,40 1 ,08 1 ,8 1 1,4 3 1 ,44
TFF3 -0 ,18 -2,0 5 -1,02 -1 ,07 -1,1 1 -0, 80 0 ,42
CSAD -0 ,20 0 ,66 -0,17 -0 ,76 -0,2 0 0,32 -0 ,11
CYB5B -0 ,22 -0,3 5 -0,41 -0 ,26 -0,4 8 -0, 13 -0 ,03
CBR1 -0 ,23 -1,4 5 -0,29 -0 ,19 -0,3 9 -0, 19 -0 ,51
DGKZ -0 ,24 0 ,28 -0,33 -0 ,02 -0,4 8 -0, 08 -0 ,36
EHHADH -0 ,26 -0,3 1 -0,34 0 ,44 -0,2 7 -0, 12 -0 ,53
GPAM -0 ,27 -0,5 9 -0,11 -0 ,55 0 ,0 0 -0, 32 -0 ,60
PCYT1A -0 ,29 0 ,45 -0,13 -0 ,10 -0,2 2 -0, 52 0 ,04
SQLE -0 ,31 -0,8 0 0,21 -0 ,11 -0,2 4 0,0 3 0 ,51
SLC25A1 -0 ,33 -0,5 2 -0,53 -0 ,15 -0,0 1 -0, 37 -0 ,62
HADHA -0 ,38 -1,3 5 -0,51 -0 ,05 -0,3 4 -0, 07 -0 ,28
BLVRB -0 ,43 -0,6 5 -0,36 -0 ,42 -0,5 0 -0, 23 -0 ,74
DNAJB2 -0 ,47 -1,9 3 -0,62 -0 ,14 -0,5 3 0,0 8 -0 ,39
ELOVL6 -0 ,51 -1,2 9 -0,63 -0 ,37 -0,5 1 -0, 15 0 ,29
SREBF2 -0 ,54 -0,7 9 -0,42 -0 ,25 -0,3 9 -0, 37 -0 ,37
NPC1 -0 ,55 -1,0 1 -0,14 -0 ,32 0 ,1 1 -0, 17 -0 ,13
ABCG5 -0 ,57 0 ,00 -0,90 -2 ,07 -1,2 4 0,0 0 0 ,00
INSIG2 -0 ,58 -0,6 0 -0,23 -0 ,38 -0,5 2 -0, 13 0 ,09
PDK1 -0 ,61 -0,6 6 -0,23 -0 ,43 -0,4 4 -0, 29 0 ,04
SCD -0 ,61 0 ,16 -0,65 -0 ,26 0 ,1 3 -1, 05 -0 ,47
ACACB -0 ,64 -0,4 4 -0,63 0 ,39 -1,2 0 -1, 12 -1 ,06
MPV17L -0 ,65 -2,3 7 -0,46 -0 ,67 -0,6 7 -0, 74 -1 ,50
PANK3 -0 ,69 -0,6 4 -0,21 -0 ,21 -0,1 6 -0, 36 -0 ,46
ACSL5 -0 ,72 -0,0 4 -0,36 -0 ,64 -0,4 1 -0, 88 -0 ,87
IDH1 -0 ,82 -0,6 1 -0,45 -0 ,75 -0,4 9 -0, 74 -1 ,04
LSS -0 ,83 -0,6 2 -0,64 -0 ,70 -1,3 0 -0, 82 -0 ,62
G6PD -0 ,83 -0,8 7 -0,77 -0 ,46 -0,8 0 -0, 76 -0 ,59
ALDOC -0 ,85 -1,7 5 -0,77 -0 ,58 -1,1 1 -0, 46 -0 ,87
SREBF1 -0 ,86 -0,6 2 -0,33 -0 ,31 -0,2 2 -0, 38 -0 ,77
TKT -0 ,87 -0,4 6 -0,86 -0 ,84 -0,6 5 -1, 03 -1 ,22
ACSL3 -0 ,89 -0,2 1 -0,22 -0 ,59 -0,1 9 -0, 44 -0 ,79
ACACA -1 ,04 -0,4 0 -0,83 -0 ,90 -0,1 7 -1, 28 -0 ,52
NSDHL -1 ,07 -1,4 0 -0,91 -0 ,77 -0,8 1 -1, 20 -1 ,60
CYP51A1 -1 ,10 -0,8 6 -0,61 -0 ,66 -1,0 4 -0, 95 -0 ,90
RDH11 -1 ,10 -0,4 7 -0,73 -0 ,93 -0,6 0 -1, 33 -1 ,53
LPIN1 -1 ,15 -0,6 1 -0,50 -0 ,84 -0,7 3 -1, 31 -1 ,23
HSD17B7 -1 ,22 -1,0 3 -0,69 -0 ,69 -0,6 7 -1, 09 -1 ,23
AACS -1 ,24 -1,4 0 -1,36 -1 ,17 -1,0 7 -1, 27 -1 ,82
LPCAT3 -1 ,25 -1,4 1 -1,01 -0 ,69 -0,5 8 -0, 91 -0 ,77
FDPS -1 ,26 -0,3 3 -1,06 -1 ,35 -0,9 3 -1, 59 -1 ,98
LDLR -1 ,28 -0,3 7 0,06 -0 ,15 -0,7 4 -0, 88 -0 ,01
EBP -1 ,28 -0,7 3 -1,05 -1 ,03 -0,9 3 -1, 46 -1 ,63
HMGCR -1 ,31 -1,6 8 -0,90 -0 ,89 -1,2 3 -1, 23 -1 ,30
FDFT1 -1 ,33 -1,3 1 -0,77 -1 ,14 -0,5 9 -2, 00 -1 ,97
MVD -1 ,39 -0,8 9 -1,30 -0 ,72 -1,1 9 -1, 52 -1 ,35
PMVK -1 ,42 -1,1 8 -1,06 -1 ,08 -1,1 1 -1, 35 -1 ,80
TM7SF2 -1 ,42 -2,0 7 -1,69 -1 ,20 -1,7 3 -1, 32 -2 ,43
SC5DL -1 ,53 -1,2 8 -0,99 -0 ,98 -0,9 0 -1, 34 -1 ,19
IDI1 -1 ,54 -1,0 2 -1,00 -0 ,83 -1,3 8 -1, 31 -0 ,83
EPB41L5 -1 ,58 -2,2 2 -1,13 -0 ,64 -1,2 5 -0, 66 -1 ,56
DHCR7 -1 ,62 -1,4 8 -1,43 -1 ,51 -1,6 1 -1, 60 -2 ,50
ELOVL5 -1 ,67 -0,5 4 -0,87 -1 ,07 -1,0 3 -2, 05 -1 ,47
ACSS2 -1 ,84 -0,6 7 -1,79 -1 ,59 -1,5 3 -2, 32 -2 ,69
ACAT2 -1 ,92 -1,2 3 -1,60 -1 ,63 -2,3 6 -2, 61 -2 ,99
FASN -2 ,04 -1,6 0 -1,73 -1 ,41 -2,1 5 -2, 28 -2 ,24
TMEM97 -2 ,07 -0,8 4 -1,73 -1 ,70 -1,9 5 -2, 50 -3 ,07
FADS2 -2 ,07 -0,5 4 -1,90 -2 ,17 -2,7 7 -3, 35 -3 ,47
FADS1 -2 ,08 -0,2 0 -1,81 -1 ,78 -1,9 7 -3, 50 -3 ,18
ME1 -2 ,10 -2,0 6 -1,46 -1 ,50 -1,7 2 -2, 02 -2 ,71
MVK -2 ,13 -1,3 2 -2,04 -1 ,20 -1,8 0 -1, 75 -1 ,87
INSIG1 -2 ,22 -1,1 2 -1,87 -2 ,08 -2,2 2 -3, 21 -2 ,42
HMGCS1 -2 ,29 -0,5 1 -1,89 -1 ,77 -2,4 4 -3, 00 -2 ,99
ELOVL3 -2 ,30 -1,7 1 -1,90 -2 ,44 -3,4 8 -3, 86 -4 ,24
THRSP -2 ,55 -0,7 3 -2,30 -2 ,43 -4,0 8 -4, 07 -4 ,39
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